WO2001062244A1 - Agents ameliorant des comportements lies a une maladie - Google Patents

Agents ameliorant des comportements lies a une maladie Download PDF

Info

Publication number
WO2001062244A1
WO2001062244A1 PCT/JP2001/000791 JP0100791W WO0162244A1 WO 2001062244 A1 WO2001062244 A1 WO 2001062244A1 JP 0100791 W JP0100791 W JP 0100791W WO 0162244 A1 WO0162244 A1 WO 0162244A1
Authority
WO
WIPO (PCT)
Prior art keywords
zaltoprofen
active ingredient
concanavalin
agent
administration
Prior art date
Application number
PCT/JP2001/000791
Other languages
English (en)
Japanese (ja)
Inventor
Toshihiro Okamoto
Original Assignee
Nippon Chemiphar Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co., Ltd filed Critical Nippon Chemiphar Co., Ltd
Priority to AU2001228876A priority Critical patent/AU2001228876A1/en
Publication of WO2001062244A1 publication Critical patent/WO2001062244A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D337/14—[b,f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the present invention relates to an agent for improving sickness behavior.
  • Background Art Symptoms Among patients suffering from diseases such as chronic liver disease, there are symptoms such as fatigue, fatigue, loss of appetite, weight loss, weakness, and reduced concentration. (Hepatology Book
  • zanoretoprofen ( ⁇ ) -12- (10,11-dihydro—10-oxodibenzo [b, fjthiepin-2-yl) propionic acid) is excellent. It is widely used in Japan as a nonsteroidal analgesic. No publications have been made indicating that zaltoprofen is effective as an agent for improving the above-mentioned sickness behavior. There is a need to provide an inhibitor for weight loss or appetite loss associated with various diseases. There is also a need to provide an improving agent for the above-mentioned thick varnish behavior. Disclosure of the invention
  • Concanavalin A-induced liver injury model (mouse) administration of Concanavalin A to experimental animals shows a decrease in body weight and food consumption of the experimental animals.
  • administration of Zaltoprofen prevented such weight loss and food consumption reduction.
  • Interleukin-1 ⁇ and TNF-a are not expressed in normal mouse brain; (Brain Research 795: 77-86 1998) Interleukin-1 and TNF- ⁇ power, however, were confirmed to be expressed in the brain in the Concanavalin A-induced liver injury model described above.
  • the present inventors have found that Zarta ⁇ -phen is effective as an improving agent for Sickness behavior and completed the present invention.
  • the present invention relates to an agent for improving Thick scabies containing zaltoprofen as an active ingredient.
  • the present invention also relates to an agent for improving weight loss associated with a disease containing zaltoprofen as an active ingredient:
  • the present invention also relates to a decrease in appetite associated with a disease containing zaltoprofen as an active ingredient.
  • the present invention relates to an agent for improving sick nis behavior associated with chronic liver disease, comprising zaltoprofen as an active ingredient.
  • Zaltoprofen, an active ingredient of the present invention is widely used as an anti-inflammatory agent, and its safety has been confirmed.
  • a preparation containing zaltoprofen as an active ingredient is useful as an agent for improving weight loss associated with diseases such as various infectious diseases, terminal stages of cancer, anorexia nervosa, and liver disease, and an agent for improving anorexia.
  • diseases such as various infectious diseases, terminal stages of cancer, anorexia nervosa, and liver disease
  • an agent for improving anorexia In human chronic liver disease, no treatment has been developed for patients to complain of so-called sick nis behavior such as fatigue, fatigue, loss of appetite, and weight loss. Thick varnish behavior is said to be triggered by the expression of site forces such as Interleukin-1 ⁇ and TNF- ⁇ in the brain.
  • the preparation containing zaltoprofen of the present invention as an active ingredient can be prepared in the same manner as in the case of using zaltoprofen as an active ingredient as an anti-inflammatory agent. That is, it can be administered to humans by an appropriate administration method such as general oral administration or parenteral administration.
  • it can be manufactured into tablets, granules, powders, capsules, suspensions, injections, suppositories and the like by usual methods in the technical field of formulation.
  • ordinary excipients, disintegrants, binders, lubricants, pigments, diluents and the like are used.
  • CMC-Ca carboxymethylcellulose cellulose
  • lubricants are used as lubricants.
  • binders hydroxypropylcellulose (HPC), gelatin, polyvinyl alcohol
  • Example 1 Formulation example (tablet) In one tablet (150mg), c active ingredient containing the following ingredients (the 40mg lactose 70
  • Ant i sense 5 '-CTCTGCAGACTCAAACTCCAC-3' TNF- a
  • Concanavalin A liver injury model the expression of mRNA of Interleukin-1; 3 and TNF-a in the brain was confirmed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

L'invention concerne des agents améliorant la perte de poids corporel ou l'anorexie liées à des maladies, telles que des affections hépatiques, et des agents améliorant des comportements liés à une maladie. Des préparations contenant zaltoprofène, en tant que principe actif, sont utilisées comme agents améliorant des comportements liés à une maladie.
PCT/JP2001/000791 2000-02-23 2001-02-05 Agents ameliorant des comportements lies a une maladie WO2001062244A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001228876A AU2001228876A1 (en) 2000-02-23 2001-02-05 Agents ameliorating sickness behaviors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000052074A JP2001233771A (ja) 2000-02-23 2000-02-23 シックニスビヘイビアに対する改善剤
JP2000-52074 2000-02-23

Publications (1)

Publication Number Publication Date
WO2001062244A1 true WO2001062244A1 (fr) 2001-08-30

Family

ID=18573644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/000791 WO2001062244A1 (fr) 2000-02-23 2001-02-05 Agents ameliorant des comportements lies a une maladie

Country Status (3)

Country Link
JP (1) JP2001233771A (fr)
AU (1) AU2001228876A1 (fr)
WO (1) WO2001062244A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6913461B2 (ja) 2014-10-30 2021-08-04 ゼリア新薬工業株式会社 シックネスビヘイビア症状改善剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001089370A (ja) * 1999-09-24 2001-04-03 Nippon Chemiphar Co Ltd 肝疾患治療剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001089370A (ja) * 1999-09-24 2001-04-03 Nippon Chemiphar Co Ltd 肝疾患治療剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUSUHARA N. ET AL.: "Effects of nonsteroidal anti-inflammatory drugs on interleukin-1 receptor antagonist production in cultured human peripheral blood mononuclear cells", PROSTAGLANDINS, vol. 54, no. 5, 1997, pages 795 - 804, XP004103804 *
SWAIN M.G. ET AL.: "Augmented interleukin-1beta-induced depression of locomotor activity in cholestatic rats", HEPATOLOGY, vol. 28, no. 6, 1998, pages 1561 - 1565, XP002938990 *

Also Published As

Publication number Publication date
AU2001228876A1 (en) 2001-09-03
JP2001233771A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
EP3290034A1 (fr) Utilisation de triméthazine dans la préparation de médicaments pour la prévention et le traitement de maladies hépatiques
JP5478486B2 (ja) 植物抽出物及びその治療的使用
CZ20004858A3 (cs) Sloučeniny získané z druhu Salvia mající protivirový účinek
KR20220088278A (ko) 오를리스타트 및 아커만시아 뮤시니필라 eb-amdk19 균주를 포함하는 조성물
CN109364074B (zh) 6-氨基烟酰胺作为有效成分在制备乙型肝炎治疗药物中的用途
CN113855654B (zh) 一种预防和治疗冠状病毒感染的组合物
US7829124B2 (en) Use of Phyllanthus constituents for treating or preventing infections caused by hepatitis B-viruses
JP2002516283A (ja) 核転写因子ＮＦ−κＢの活性化の阻害剤としての２−ヒドロキシ−４−トリフルオロメチル安息香酸誘導体の使用
JP5118863B2 (ja) 催眠用医薬組成物
TW201211041A (en) Agent for preventing or treating nonalcoholic steatohepatitis
WO2001062244A1 (fr) Agents ameliorant des comportements lies a une maladie
PT951281E (pt) 2-ciclopenten-1-ona e seus derivados como inibidores do factor nf-kb
CN106822152B (zh) 一种药物组合物及其应用
JP2023110110A (ja) ＳＡＲＳ－ＣｏＶ－２感染症の治療、予防または緩和用組成物
US20210393727A1 (en) Composition comprising nigella sativa oil and surface-active agents
WO2012058795A1 (fr) Utilisations d'acides gras insaturés pour inhiber la réplication de virus et/ou l'infection par des virus
JPH09241157A (ja) リソスペルメートｂ含有肝臓保護作用医薬組成物
JP2004262929A (ja) α−グルコシダーゼ阻害剤
JPH0643328B2 (ja) 冠血管拡張剤
US20120058121A1 (en) Methods and compositions for treating lupus
JP4547892B2 (ja) α−グルコシダーゼ阻害剤
JP2003226650A (ja) 医薬用組成物
Ighorodje et al. Colchicine and Vitamin E in the management of paracetamol-induced liver damage
JP2001089370A (ja) 肝疾患治療剤
US20220226414A1 (en) COVID-19 Treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase